New Market Report: Global Breast Cancer Market 2014-2018

From: Fast Market Research, Inc.
Published: Fri Jul 11 2014


Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer and other undifferentiated carcinoma. Ductal carcinoma is the form of breast cancer which starts in the lining of the milk ducts while lobular carcinoma begins in the milk glands of the breast. When breast cancer spreads from the site of origin to surrounding tissue, it is known as invasive breast cancer. Invasive ductal carcinoma is the most common subtype accounting for 70 to 80 percent of all the breast cases. In women, breast cancer is the second most common form of cancer. GLOBOCAN reported that in the year 2012, breast cancer accounted for 11.9 percent of the total cancer cases and lead to 5,22,000 deaths worldwide.

Full Report Details at
- http://www.fastmr.com/prod/842596_global_breast_cancer_market_20142018.aspx?afid=301

TechNavio's analysts forecast the Global Breast Cancer market will grow at a CAGR of 11.61 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Breast Cancer market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sale of drugs used for the management of breast cancers including but not limited to:

* HER2-negative breast cancer
* HER2-positive breast cancer
* Hormone receptor positive breast cancer
* Hormone receptor negative breast cancer
* Advanced breast cancer
* Early breast cancer
* Operable node positive breast cancer
* Metastatic breast cancer
* Triple Negative Breast Cancer

The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Breast Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Breast Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

* Americas
* EMEA
* APAC

Key Vendors

* Astrazeneca PLC
* Eli Lilly and Company
* F. Hoffmann-La Roche Ltd
* Novartis AG
* Sanofi-Aventis

Other Prominent Vendors

* Accord Healthcare, Inc.
* Pfizer, Inc.
* Hospira, Inc.
* Actavis, Inc.
* Bayer AG
* BioMarin Pharmaceutical Inc.
* Bristol-Myers Squibb Company

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014
- Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth
- Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options
- Metastatic Breast Cancer - Pipeline Review, H1 2014
- Breast Cancer - Pipeline Review, H1 2014
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »